Venetoclax was initially approved in 2016 as a monotherapy for relapsed CLL patients with del(17p) or TP53 mutation or who are not suitable for BCR inhibitors, as well as for patients without del(17p) or TP53 mutation and refractory to CIT and BCR pathway inhibitors. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.